LGVN
Longeveron Inc. Common Stock
Latest price
As of Oct 26, 2026, 4:00 PM EDT · Market data by Massive
Market cap
$5.1M
Volume
91.2K
Previous close
$1.60
Day range
$1.50 – $1.86
Listed
Feb 12, 2021
Coverage
12 articles
Price performance
Recent trading
Newsroom
Latest LGVN coverage
Long-term Survival Data from Longeveron’s ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association
Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today an abstract highlighting long-term survival data from the Company’s ELIPS 1 t
Longeveron to Participate in the 149th Annual National Investment Banking Association Conference
Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today that the Company’s management will be participating in the 149th Annual Confe
Longeveron Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-BTM in Hypoplastic Left Heart Syndrome
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today the Phase 2 ELPIS II trial, funded by the National Heart, Lung, and Blood Institute (NHLBI) and using the Company’s Lomecel-BTM asset in Hypoplastic Left Heart Syndrome (HLHS), has su
Presenting on the Emerging Growth Conference on August 9 & 10 Register Now
EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 60th Emerging Growth Conference on August 9, 10, 2023.
Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer
Longeveron Inc. (NASDAQ: LGVN) , a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today the appointment of Nataliya Agafonova, M. D., as the Company’s Chief Medical Officer (CMO), effective as of July 1, 2023. As CMO, Dr. Agafonova will lead Longeveron’s global clinical
Longeveron Congratulates Co-Founder and Chairman Dr. Joshua Hare on Induction as Fellow of National Academy of Inventors
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today that Chairman, Co-founder and Chief Science Officer Joshua Hare, MD, FACC, has been inducted as a fellow of the prestigious National Academy of Inventors (NAI) in recognition of his le
Longeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-BTM for the Treatment of Alzheimer’s Disease
Longeveron Inc. (NASDAQ: LGVN) announced today, the completion of enrollment in its Phase 2a trial of Lomecel-BTM in patients with mild Alzheimer’s Disease (AD).
Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B™ Cell Therapy Through Levels of Vascular Biomarker
Issued claims will protect use of a biomarker to assess response to Lomecel-B in patients with blood vessel dysfunction. Miami, Florida – August 25, 2022 – Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, today announced that the European Pat
Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer’s Trial
This third collaboration with the Miami VA shows Longeveron’s commitment to improving the health of our nation’s Veterans. Miami, Florida – April 13, 2022 – Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announce
Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s Disease
Trial designed to obtain safety and efficacy data of single and multiple dosing regimen Miami, Florida—January 5, 2021— Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today the initiation of its Ph
U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition
Phase 2 clinical trial underway for Hypoplastic Left Heart Syndrome, which affects approximately 1,000 babies per year Miami, Florida—November 18th, 2021— Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today t
Longeveron Announces Abstract Highlighting Data from Phase 1 Alzheimer’s Disease Trial Accepted for Developing Topics Presentation at the 2021 Annual Alzheimer's Association International Conference
Miami, Florida – June 24th, 2021 – Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for aging-related and chronic disease, announced today that an abstract summarizing the results of its Phase 1 trial of Lomecel-B infusion for patients with mild Alzheimer’s disease has been accepted for a Developing T